Navigation Links
FDA approves IND on Lead Product M6G

CAMBRIDGE, England, 26th April 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, today announces that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of morphine-6-glucuronide (M6G), its novel drug for the treatment of post-operative pain. Earlier this year, CeNeS announced results of a Phase III study of M6G in Europe in over 500 patients with post-operative pain. The study demonstrated that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV). The opening trial under this IND will be a Phase I pharmacokinetic study in volunteers. This study is required by the FDA as is an additional pre-clinical toxicology analysis before progressing to Phase III trials. CeNeS is currently completing the protocol design of the first US Phase III trial. The filing of the IND enhances the package of data already available to potential US partners for review. Neil Clark, Chief Executive of CeNeS, said:

"The FDA's approval of our IND application for M6G is a major landmark in CeNeS' clinical development programme. North America is an attractive market for our drug candidate and M6G is clearly positioned to be a genuine alternative to standard morphine therapy."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have shown that M6G given intravenously produces equivalent analgesia to morphine to combat post-operative pain. Studies have also shown that M6G reduced the incidence of nausea and vomiting when compared directly with morphine. Other studies published recently in the scientific literature demonstrate that M6G also reduces respiratory depression compared to morphine.

The global market for opiate use in managing post-operative pain was estimated at $1 billion in 2000 and growing at a rate of 6-7%.


'"/>




Related medicine technology :

1. FDA approves MyocondaR IND for MAP in Crohns Disease
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
4. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
5. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
6. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
7. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
8. PromegaExpress Expands Easy Access to Products with New Cabinet
9. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
10. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
11. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Scope of the Report The report titled "Global ... (2016-2020)", provides an in-depth analysis of the global continence ... The market also provides an in-depth analysis of intermittent ... regional analysis of continence care market, including the following ... Europe and Rest of the World. The ...
(Date:1/23/2017)... The Pharmacy Technician Certification Board (PTCB) ... planned 2020 accredited education requirement for pharmacy technicians ... 2013 that the requirement would take effect in ... program changes designed to keep pace with the ... "We have determined that additional deliberation ...
(Date:1/23/2017)... YORK , Jan. 23, 2017 Consolidated ... Partners and Driving the Stability Testing Outsourcing Market ... market addresses market sizing, emerging trends, and technologies, and ... market. The base year is 2015 and forecasts are ... is expected to grow at a CAGR of 9.4% ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... 24, 2017 , ... “The Octagon of Spiritual Balances”: a guide for ... the creation of published author, Pastor Bernard J. Weathers, pastor of Word of Faith ... in religious education and a master degree in theology. , ““The Octagon of Spiritual ...
(Date:1/24/2017)... ... January 23, 2017 , ... The Pharmacy ... 20, with the bipartisan original co-sponsorship of nearly one-quarter of the U.S. House ... National Association of Chain Drug Stores (NACDS) strongly backs the legislation. , “NACDS ...
(Date:1/24/2017)... Dallas, Texas (PRWEB) , ... January 23, 2017 ... ... expanding its presence in Texas with the acquisitions of two personal care service ... (PAS), in Texas City, Texas, effective January 1, 2017. , Well regarded in ...
(Date:1/24/2017)... ... January 24, 2017 , ... The National Council of Alcoholism and ... alcohol awareness, have worked with communities to designate the last full week of January ... the theme is “Shatter the Myths.” As a community, we can advocate for ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... nonprofit educational institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 ... present by Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. ...
Breaking Medicine News(10 mins):